Literature DB >> 2908720

Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.

S Ghiringhelli1, E Cozzi, D Tsialtas.   

Abstract

The antihypertensive effects of once-daily administration of celiprolol 400 mg were compared with those of once-daily enalapril 20 mg in 20 mild to moderate essential hypertensives in a single-blind study in which the subjects were randomized to 2 weeks' treatment with either drug, preceded by 2 weeks of placebo administration. Supine and standing systolic blood pressure (SBP), diastolic pressure (DBP), and heart rate (HR) were measured at rest and during exercise (exercise bicycle with increasing work loads up to 100 watts) at the end of either period, 20 to 24 hr after drug or placebo administration. Compared to placebo, both celiprolol and enalapril reduced resting supine and standing SBP and DBP to a marked and similar extent; resting HR was unaffected by enalapril, while celiprolol produced modest reductions. During exercise, however, celiprolol significantly attenuated rises in SBP and HR, while enalapril did not. Indexes of cardiac function at rest obtained by echocardiography and systolic time intervals were unaffected by either drug. Thus, despite similar reductions by both drugs in resting blood pressures, celiprolol produced better antihypertensive effects during exercise than enalapril.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908720     DOI: 10.1007/BF00051236

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  21 in total

Review 1.  Beta-blocking drugs and myocardial function.

Authors:  S H Taylor
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

Review 2.  Effects of celiprolol on reflex control of the cardiovascular system in essential hypertension.

Authors:  G Mancia; G Grassi; G Parati; G Pomidossi; E Sabadini; C Giannattasio; G Bolla; A Zanchetti
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  Comparative effects of propranolol and pindolol on small and large arteries and veins of the forearm circulation in hypertensive man.

Authors:  B L Maarek; J A Bouthier; A C Simon; J A Levenson; M E Safar
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease.

Authors:  G Gensini; C Dator; P Esente; F S Caruso; T Solomon
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

5.  Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension.

Authors:  L Hansson; A J Zweifler; S Julius; S N Hunyor
Journal:  Acta Med Scand       Date:  1974 Jul-Aug

6.  The effect of celiprolol on peripheral circulation in healthy volunteers.

Authors:  H Ehringer; U Konecny; W Rasser
Journal:  Br J Clin Pract Suppl       Date:  1985-06

7.  Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress.

Authors:  R B Devereux; T G Pickering; G A Harshfield; H D Kleinert; L Denby; L Clark; D Pregibon; M Jason; B Kleiner; J S Borer; J H Laragh
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

8.  Hemodynamic and volume changes associated with captopril.

Authors:  R C Tarazi; E L Bravo; F M Fouad; P Omvik; R J Cody
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

9.  Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.

Authors:  R G Van Inwegen; A Khandwala; I Weinryb; T P Pruss; E Neiss; C A Sutherland
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-11

10.  Enalapril and autonomic reflexes and exercise performance.

Authors:  J L Reid; J A Millar; B C Campbell
Journal:  J Hypertens Suppl       Date:  1983-10
View more
  1 in total

Review 1.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.